Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Research & Development: 2020-2025

Historic Research & Development for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $43.0 million.

  • Mirum Pharmaceuticals' Research & Development rose 35.48% to $43.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $179.1 million, marking a year-over-year increase of 40.43%. This contributed to the annual value of $140.6 million for FY2024, which is 37.05% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Research & Development is $43.0 million, which was down 6.74% from $46.1 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Research & Development ranged from a high of $46.1 million in Q2 2025 and a low of $22.0 million during Q2 2023.
  • In the last 3 years, Mirum Pharmaceuticals' Research & Development had a median value of $32.2 million in 2024 and averaged $34.4 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Research & Development spiked by 119.92% in 2021 and then tumbled by 36.83% in 2022.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Research & Development stood at $27.8 million in 2021, then grew by 11.99% to $31.1 million in 2022, then decreased by 0.55% to $30.9 million in 2023, then spiked by 42.32% to $44.0 million in 2024, then soared by 35.48% to $43.0 million in 2025.
  • Its Research & Development stands at $43.0 million for Q3 2025, versus $46.1 million for Q2 2025 and $46.0 million for Q1 2025.